Navigation Links
Beaumont, U-M Open Study of Drug for Advanced Breast Cancer
Date:10/28/2009

ticipants are randomly assigned to study groups and will know which treatment regimen they are receiving. Women initially assigned to the group that does not receive the study drug will have the opportunity to receive the study drug if their disease worsens during treatment with chemotherapy alone. This trial is underway at multiple sites throughout the country and is expected to conclude enrollment by the end of the year.

To participate in the trial, patients must have:

 
  • a diagnosis of metastatic TNBC
  • completed no more than two rounds of chemotherapeutic treatments for metastatic disease
  • disease that is measurable on an imaging study
"The PARP inhibitors represent a novel cancer treatment that holds great promise for many patients with cancer," says Dana Zakalik, M.D., director of the Beaumont Cancer Genetics Program and principal investigator at Beaumont. "They provide hope for patients with this particularly aggressive breast cancer for whom conventional treatments were lacking."

Triple negative breast cancer is a subtype of breast cancer that accounts for about one in five breast cancer diagnoses. Subtypes of breast cancer are based on the presence of three receptors that are known to fuel tumor growth and spread of cancer. These receptors are estrogen, progesterone and human epidermal growth factor or HER2. Existing therapies bind to or otherwise inhibit the receptors, thus impeding tumor growth. In TNBC, none of these
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Let Kids Sleep Late on Weekends to Fight Fat: Study
2. NeoVista Presents Interim Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
3. Old, New Pap Methods Equally Good, Dutch Study Finds
4. Stanford study recommends change in treating pulmonary embolisms
5. Deadly stomach infection rising in community settings, Mayo Clinic study finds
6. Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients
7. Mayo Clinic study shows people with heart devices can digest advanced diagnostic technology safely
8. Wolves lose their predatory edge in mid-life, new U of Minnesota study shows
9. Study finds delay in follow-up among African-American women receiving abnormal breast finding
10. STAAR Surgical Collamer(R) Accommodating Study Team Reports First Phase Assessments at AAO
11. After Tonsillectomy, Short-Term Antibiotics Effective: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Beaumont, U-M Open Study of Drug for Advanced Breast Cancer 
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... fitness classes. , Starting September 1st they are offering pre and ... Bod" and "Healthy Body, Healthy Baby." , More information can be found at ...
(Date:8/31/2015)... ... , ... Coast Dental Vista is celebrating its recent grand opening ... p.m. near Albertsons in the Foothill Center, located at 1279 E. Vista Way. There ... Jay Lopp. Call (760) 208-2518 for more details or stop by on September 5. ...
(Date:8/31/2015)... ... ... In an article published August 24th on Healio, the author ... discusses the future of 3-D printing technology as it relates to the field of ... other 3-D printed tools could be used to aid in the treatment of patients ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Program at Monmouth, was one of the first doctors in the area to ... this new approach have been impressive: faster recovery, decreased immediate and long-term pain, ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4
... Researchers at Mount Sinai School of Medicine have found ... phytoestrogensin young girls may disrupt the timing of pubertal ... later in life. The study, the first to examine ... currently published online in the journal Environmental Health ...
... Development, a global health and development consulting group based ... aims to improve global health by helping to turn ... or E2Pi, officially launches this week in San Francisco ... world,s major health challenges including HIV, tuberculosis, malaria, ...
... Students from around ... to becoming the first iPad developers to debut their apps on the iTunes App Store. ... Scottsdale, Arizona (PRWEB) April ... iPad programming and marketing training, has successfully added another course to their training catalog: “iPad ...
... and antidepressants found in some pills, researchers say, , ... the Internet as "natural," the popular weight loss ... ingredients, researchers say. , The U.S. Food and Drug ... the diet pills, but they remain popular and easy ...
... team of Swedish and American scientists has shown for the ... an enzyme myeloperoxidase (MPO) found in white blood ... and contradict what was previously believed, that carbon nanotubes are ... scientists hope that this new understanding of how MPO converts ...
... ... and author, Hope Warshaw, MMSc, RD, CDE, has updated her best-selling guide to making sense ... for food shopping and eating out for people with diabetes. On HealthyOutcomes.com, visitors can ... ...
Cached Medicine News:Health News:Exposure to 3 classes of common chemicals may affect female development 2Health News:New global health initiative will help bridge gap between knowledge, action 2Health News:First iPad App Developers Graduate from Around the Globe: Ready to Show Their New Apps 2Health News:Online Brazilian Diet Pills Can Be Addictive 2Health News:Online Brazilian Diet Pills Can Be Addictive 3Health News:New study on carbon nanotubes gives hope for medical applications 2Health News:New Book Offers Final Answer to 'What's for Dinner?' for People with Diabetes and Those Who Love Them 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: